Prognostic Significance of Circulating Tumor Cells in Patients With Hormone Refractory Prostate Cancer

Journal of Urology

Volumn 181, Issue 3, 2009, Pages 1091-1097

  Okegawa, Takatsugu ^a   Nutahara, Kikuo ^a   Higashihara, Eiji ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

neoplasm circulating cells; neoplasm metastasis; prognosis; prostate; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CANCER ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE; FLUTAMIDE; PROSTATE CANCER ANTIBODY; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCHEMICAL EQUIPMENT; BLOOD ANALYSIS; BLOOD SAMPLING; BLOOD VOLUME; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION; CELL ASSAY; CELL COUNT; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE METASTASIS; TUMOR CELL;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT FAILURE;

EID: 59349109415     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.11.015     Document Type: Article

References (17)

1. Okegawa T., Noda H., Kato M., Miyata A., Nutahara K., and Higashihara E. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 44 (2000) 210
2. Loberg R.D., Fridman Y., Pienta B.A., Keller E.T., McCauley L.K., Taichman R.S., et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia 6 (2004) 302
3. Ross R.W., Manola J., Hennessy K., Galsky M., Scher H., Small E., et al. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res 11 (2005) 5195
4. Ghossein R.A., Rosai J., Scher H.I., Seiden M., Zhang Z.F., Sun M., et al. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostate carcinoma. Urology 50 (1997) 100
5. Kagan M., Howard D., Bendele T., Mayes J., Silvia J., Repollet M., et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 25 (2002) 104
6. Moreno J.G., Miller M.C., Gross S., Allard W.J., Gomella L.G., and Terstappen L.W. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65 (2005) 713
7. Garcia J.A., Rosenberg J.E., Weinberg V., Scott J., Frohlich M., Park J.W., et al. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 99 (2007) 519
8. Danila D.C., Heller G., Gignac G.A., Gonzalez-Espinoza R., Anand A., Tanaka E., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13 (2007) 7053
9. Okegawa T., Nutahara K., and Higashihara E. Immunomagnetic quantification of circulating tumors cell as a prognostic factor of androgen-deprivation responsiveness in hormone-naive metastatic prostate cancer patients. J Urol 180 (2008) 1342
10. Shaffer D.R., Leversha M.A., Danila D.C., Lin O., Gonzalez-Espinoza R., Gu B., et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13 (2007) 2023
11. Nakanishi H., Kodera Y., Yamamura Y., Ito S., Kato T., Ezaki T., et al. Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the LightCycler. Int J Cancer 20 (2000) 89. : 411
12. Soloway M.S., Hardeman S.W., Hickey D., Raymond J., Todd B., Soloway S., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1998) 195
13. Shulman M.J., and Benaim E.A. The natural history of androgen independent prostate cancer. J Urol 172 (2004) 141
14. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 (2004) 781
15. Cristofanilli M., Gonzalez-Angulo A., Sneige N., Kau S.W., Broglio K., Theriault R.L., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23 (2005) 1420
16. Chen B.T., Loberg R.D., Neeley C.K., O'Hara S.M., Gross S., Doyle G., et al. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 65 (2005) 616
17. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14 (2008) 6302